Pharmagreen Biotech Inc.
PHBI · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.02 | -0.00 | -0.00 |
| FCF Yield | -0.64% | -0.88% | -0.69% | 0.04% |
| EV / EBITDA | 17.05 | -11.22 | 2.10 | -4.08 |
| Quality | ||||
| ROIC | 2.20% | 2.23% | 3.00% | 1.81% |
| Gross Margin | -383.58% | 41.44% | 44.57% | 25.15% |
| Cash Conversion Ratio | -0.08 | 0.07 | -0.01 | -0.00 |
| Growth | ||||
| Revenue 3-Year CAGR | 13.83% | 38.91% | 144,157.00% | 150,416.74% |
| Free Cash Flow Growth | 59.23% | -36.23% | -747.04% | 263.54% |
| Safety | ||||
| Net Debt / EBITDA | 6.34 | -2.80 | 0.55 | -0.46 |
| Interest Coverage | -4.78 | -6.00 | -7.39 | -6.06 |
| Efficiency | ||||
| Inventory Turnover | 0.25 | 0.05 | 0.06 | 0.05 |
| Cash Conversion Cycle | -24,613.79 | -180,193.04 | -153,088.96 | -189,911.31 |